Worldwide Licensing Agreements and Stock Price Movements in HealthCare Companies - Research Report on Baxter, ResMed, PAREXEL, The Cooper Companies, and Thoratec Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, November 22, 2013 NEW YORK, November 22, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Baxter International Inc. (NYSE: BAX), ResMed Inc. (NYSE: RMD), PAREXEL International Corporation (NASDAQ: PRXL), The Cooper Companies, Inc. (NYSE: COO), and Thoratec Corporation (NASDAQ: THOR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Baxter International Inc. Research Report On November 15, 2013, Baxter International Inc. (Baxter) and Cell Therapeutics, Inc. (CTI) jointly announced an exclusive worldwide licensing agreement to develop and commercialize pacritinib - a novel investigational JAK2/FLT3 inhibitor with activity against genetic mutations linked to myelofibrosis, leukemia and certain solid tumors. The companies said that pacritinib is currently in Phase III development for patients with myelofibrosis, a chronic malignant bone marrow disorder. Under the terms of agreement, Baxter gains exclusive commercialization rights for all indications for pacritinib outside the United States, while Baxter and CTI will together commercialize pacritinib in the United States. "We believe Baxter represents the ideal strategic partner to achieve the full potential of pacritinib," said James A. Bianco, M.D., President and CEO of CTI. "Our two companies share a dedication to oncology and a vision for bringing this unique oral JAK2/FLT3 inhibitor to patients with certain blood cancers and solid tumors. This collaboration will provide additional financial resources and commercial expertise to position us to pursue the development, commercialization and market potential of pacritinib." The Full Research Report on Baxter International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/163d_BAX -- ResMed Inc. Research Report On November 19, 2013, ResMed Inc.'s (ResMed) shares rose 0.32% to end the trading session at $50.89. Shares of ResMed slipped 1.18% over the past three trading sessions, while the Dow Jones Industrial Average Index rose 0.57% during the same period. The Full Research Report on ResMed Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/bd44_RMD -- PAREXEL International Corporation Research Report On November 19, 2013, shares of PAREXEL International Corporation (PAREXEL) dropped 1.76% to end the day at $41.41. Over the previous three trading sessions, PAREXEL's shares dropped 5.67% as compared to the Dow Jones Industrial Average Index, which rose 0.57% during the same period. Full Research Report on PAREXEL International Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/067b_PRXL -- The Cooper Companies, Inc. Research Report On November 19, 2013, shares of The Cooper Companies, Inc. (The Copper Companies) dipped 0.03% to end the trading session at $127.96. Shares of the Company rose 0.77% over the past three trading sessions, while the Dow Jones Industrial Average Index rose 0.57% during the same period. The Full Research Report on The Cooper Companies, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/9cde_COO -- Thoratec Corporation Research Report On November 19, 2013, shares of Thoratec Corporation (Thoratec) dropped 1.64% to end the trading session at $41.99. Thoratec's shares dropped 2.39% over the three previous trading sessions, while the NASDAQ composite Index dropped 1.04% during the same period. The Full Research Report on Thoratec Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/1bee_THOR ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Worldwide Licensing Agreements and Stock Price Movements in HealthCare Companies - Research Report on Baxter, ResMed, PAREXEL,
Press spacebar to pause and continue. Press esc to stop.